CFRA Downgrades Novo Nordisk (NVO) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NVO Hot Sheet
Price: $39.05 -0.96%
Rating Summary:
8 Buy, 16 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
8 Buy, 16 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
CFRA analyst Wan Nurhayati downgraded Novo Nordisk (NYSE: NVO) from Hold to Sell with a price target of $38.00.
For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.
Shares of Novo Nordisk closed at $39.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
- Graphano Energy amends private placement to add flow-through shares
- Zefiro Methane closes C$5M non-brokered private placement
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
